24May 2021
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants threatens progress toward control of the coronavirus disease 2019 (Covid-19) pandemic. In a phase 1–2 trial involving healthy adults, the NVX-CoV2373 nanoparticle vaccine had an acceptable safety profile and was associated with strong neutralizing-antibody and antigen-specific polyfunctional CD4+ T-cell responses. Evaluation of vaccine efficacy was needed in a setting of ongoing SARS-CoV-2 transmission...

  • #family health

Like

Save

Share